Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer – a pilot study
Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years and need complete bladder excision. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate feasibility, safety and therapeutic efficacy of the α-emitter radioimmunoconjugate in recurrent bladder cancer patients.
SCHEIDHAUER Klemens;
SEIDL C.;
BRUCHERTSEIFER Frank;
APOSTOLIDIS Christos;
AUTENRIETH Michael;
KURTZ F;
HORN Thomas;
SCHWAIGER Markus;
GSCHWEND J.E.;
D'ALESSANDRIA C;
PFOB C;
SENEKOWITSCH-SCHMIDTKE Reingard;
MORGENSTERN Alfred;
2017-08-01
European Commission - Joint Resarch Centre
JRC106154
Additional supporting files
| File name | Description | File type | |
|---|
